Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

18.96 +0.47 (+2.54%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

February 19, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Preview: Relay Therapeutics's Earnings ↗

August 06, 2025

Via Benzinga

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗

February 06, 2026

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

February 03, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

December 16, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

December 12, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗

December 03, 2025

Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Topics Artificial Intelligence Economy Emissions

Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗

November 06, 2025

Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029.

Via Chartmill

Topics Earnings

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

November 06, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

November 03, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

October 30, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗

September 05, 2025

The cancer-focused biotech has a bright future, according to one pundit.

Via The Motley Fool

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

August 28, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 26, 2025

Via Benzinga

Relay (RLAY) Q2 Loss Narrows 41% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

August 07, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

July 31, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 02, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

May 05, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

April 28, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.